Sight Sciences, Inc. (SGHT)
Sight Sciences, Inc. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Menlo Park, CA, US. The stock last traded at $8.23, up 6.26% on the session, giving a market capitalisation of $448.1M. On trailing twelve-month figures it carries a trailing P/E of -14.75, a net margin of -35.7%. Its beta of 2.38 implies it has historically moved more than the broad market.
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Sight Sciences, Inc. is most often compared with the following Healthcare names: